Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus

British Journal of Clinical Pharmacology

Volumn 56, Issue 1, 2003, Pages 112-119

  Ogutu, Bernhards R ^a,b,d   Newton, Charles R J C ^a,c   Muchohi, Simon N ^d   Otieno, Godfrey O ^a   Edwards, Geoffrey ^e,f   Watkins, William M ^e   Kokwaro, Gilbert O ^b,d  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Fosphenytoin; Malaria; Pharmacokinetics; Phenytoin; Status epilepticus

Indexed keywords

CHLORAMPHENICOL; FOSPHENYTOIN SODIUM; PENICILLIN G; PHENOBARBITAL; PHENYTOIN; THIOPENTAL;

ADOLESCENT; ARTICLE; BACTERIAL MENINGITIS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BRADYCARDIA; BREATHING RATE; CARDIOVASCULAR EFFECT; CHILD; CLINICAL ARTICLE; CONSCIOUSNESS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFECT; DRUG FATALITY; DRUG INFUSION; EPILEPTIC STATE; FEMALE; HUMAN; HYPOTENSION; MALARIA; MALE; MIDDLE CEREBRAL ARTERY; PRIORITY JOURNAL; RESPIRATION DEPRESSION; TRANSCUTANEOUS OXYGEN MONITORING; TREATMENT OUTCOME;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALARIA, FALCIPARUM; MALE; PHENYTOIN; STATUS EPILEPTICUS;

EID: 0037998724     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01829.x     Document Type: Article

References (46)

1. Newton CR, Krishna S. Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacol Ther 1998; 79: 1-53.
2. Shorvon S. Emergeny treatment of status epilepticus. In Status epilepticus: Its clinical features and treatment in childhood and Adults. Cambridge: Cambridge University Press; 1994.
3. Holding PA, Stevenson J, Peshu N, Marsh K. Cognitive sequelae of severe malaria with impaired consciousness. Trans R Soc Trop Med Hyg 1999; 93: 529-534.
4. Waruiru CM, Newton CR, Forster D, et al. Epileptic seizures and malaria in Kenyan children. Trans R Soc Trop Med Hyg 1996; 90: 152-155.
5. Crawley J, Smith S, Kirkham F, et al. Seizures and status epilepticus in childhood cerebral malaria. Quart J Med 1996; 89: 591-597.
6. Newton CR, Marsh K, Peshu N, Kirkham FJ. Perturbations of cerebral hemodynamics in Kenyans with cerebral malaria. Pediatr Neurol 1996; 15: 41-49.
7. Serrano EE, Wilder BJ. Intramuscular administration of diphenylhydantoin. Histologic follow-up studies. Arch Neurol 1974; 31: 276-278.
8. Cranford RE, Leppik IE, Patrick B, Anderson CB, Kostick B. Intravenous phenytoin: clinical and pharmacokinetic aspects. Neurology 1978; 28: 874-880.
9. Jamerson BD, Dukes GE, Brouwer KL, et al. Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy 1994; 14: 47-52.
10. Morton LD. Clinical experience with fosphenytoin in children. J Child Neurol 1998; 13(Suppl 1): S19-S22; discussion S30-12.
11. Wheless JW. Pediatric use of intravenous and intramuscular phenytoin: lessons learned. J Child Neurol 1998; 13(Suppl 1): S11-S14; discussion S30-12.
12. Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. N Engl J Med 1995; 332: 1399-1404.
13. Ogutu BR, Newton CR, Crawley J, et al. Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions. Br J Clin Pharmacol 2002; 53: 49-57.
14. Berkley JA, Mwangi I, Mellington F, Mwarumba S, Marsh K. Cerebral malaria versus bacterial meningitis in children with impaired consciousness. Quart J Med 1999; 92: 151-157.
15. Newton CR, Kirkham FJ, Winstanley PA, et al. Intracranial pressure in African children with cerebral malaria. Lancet 1991; 337: 573-576.
16. Ogutu BR. Pharmacokinetic and pharmacodynamic study of diazepam, paraldehyde, phenytoin, fosphenytoin and phenobarbitone in Kenyan children with severe malaria. PhD Thesis, Department of Pharmaceutics and Pharmacy Practice, University of Nairobi, 2002.
17. Adams RJ, Nicholas FT, Hess DC. Normal values and physiological variables. In Transcranial Doppler, 1st edn, eds Newell DW, Asalid R. New York: Raven Press, 1992; 41-48.
18. Aslid R. Development and Principles of Transcranial Doppler. In Transcranial Doppler, edition 1st edn, eds Newell DW, Asalid R. New York: Raven Press, 1992; 1-8.
19. Newton CR, Chokwe T, Schellenberg JA, et al. Coma scales for children with severe falciparum malaria. Trans R Soc Trop Med Hyg 1997; 91: 161-165.
20. Cwik MJ, Liang M, Deyo K, Andrews C, Fischer J. Simultaneous rapid high-performance liquid chromatographic determination of phenytoin and its prodrug, fosphenytoin in human plasma and ultrafiltrate. J Chromatogr B Biomed Sci Appl 1997; 693: 407-414.
21. Aynacioglu AS, Brockmoller J, Bauer S, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409-415.
22. Heinzel G, Woloszczak R, Thomann P. Topfu (Version 2.0). Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Stuttgart: Gustav Fischer; 1993.
23. Wagner JG. Simple Nonlinear Models. In Pharmacokinetics for the Pharmaceutical Scientist, 1st edn. Lancaster: Technomic Publishing Co., 1993; 128.
24. Ogutu BR, Newton CRJC, Muchohi SN, Otieno GO, Kokwaro G. Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol co-administration. Br J Clin Pharmacol 2002; 54: 635-642.
25. Altman DG, Machin D, Bryant TN, Gardner MJ. Statistics with confidence, 2nd edn. Bristol: BMJ Books, 2000.
26. Child Advocacy International. Normal values for vital clinical signs and laboratory measurements. In: International Child Health Care: a practical manual for hospitals worldwide. 1st edn. Southall D, Coulter B, Ronald C, Nicholson S, Parke S (Eds). London: BMJ Books, 2002; p 594-595.
27. Kugler AR, Knapp LE, Eldon MA. Rapid attainment of therapeutic phenytoin concentrations following administration of loading doses of fosphenytoin. A metaanalysis. Neurology 1996; 46: A176.
28. Eldon MA, Loewen GR, Voightman RR. Pharmacokinetics and tolerance of fosphenytoin and phenytoin administered to healthy subjects. Can J Neurol Sci 1993; 20: S180.
29. Jamerson BD, Donn KH, Dukes GE, et al. Absolute bioavailability of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9653 administration to humans. Epilepsia 1990; 31: 592-597.
30. Pryor FM, Gidal B, Ramsay RE, DeToledo J, Morgan RO. Fosphenytoin pharmacokinetics and tolerance of intramuscular loading doses. Epilepsia 2001; 42: 245-250.
31. Quon CY, Stampfi HK. In vitro hydrolysis of ACC-9653 (phosphate ester prodrug of phenytoin) by human, dog, rat blood and tissues [abstract]. Pharm Res 1986; 3(Suppl): 134S.
32. Boucher BA. Fosphenytoin. A novel phenytoin prodrug. Pharmacotherapy 1996; 16: 777-791.
33. Odar-Cederlof I, Borga O. Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid. Clin Pharmacol Ther 1976; 20: 36-47.
34. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications, 2nd edn. Philadelphia: Lea & Febiger, 1989; 152-156.
35. Buchanan RA, Heffelfinger JC, Weiss CF. The effect of phenobarbital on diphenylhydantoin metabolism in children. Pediatrics 1969; 43: 114-116.
36. Garrettson LK, Dayton PG. Disappearance of phenobarbital and diphenylhydantoin from serum of children. Clin Pharmacol Ther 1970; 11: 674-679.
37. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (Part II). Clin Pharmacokinet 1990; 18: 131-150.
38. Koren G, Barzilay Z, Schachar E, et al. Kinetics of CSF phenytoin in children. Can J Neurol Sci 1983; 10: 195-197.
39. Koren G, Lavi S, Greenwald M, et al. Cerebrospinal fluid pharmacokinetics of tobramycm, ceftazidime, phenobarbitone and phenytoin in a child. Clin Pharmacokinet 1985; 10: 371-375.
40. Brown H, Hien TT, Day N, et al. Evidence of blood-brain barrier dysfunction in human cerebral malaria. Neuropathol Appl Neurobiol 1999; 25: 331-340.
41. Jurgens G, Christensen HR, Brosen K, et al. Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans. Clin Pharmacol Ther 2002; 71: 214-220.
42. Naidu S, Payne AJ, Moodley J, Hoffmann M, Gouws E. Randomised study assessing the effect of phenytoin and magnesium sulphate on maternal cerebral circulation in eclampsia using transcranial Doppler ultrasound. Br J Obstet Gynaecol 1996; 103: 111-116.
43. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339: 792-798.
44. Shinnar S, Berg AT, Moshe SL, Shinnar K. How long do new-onset seizures in children last? Ann Neurol 2001; 49: 659-664.
45. Potschka H, Wolfgang L. In vivo evidence for P-Glycoprotein mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001; 42: 1231-1240.
46. McLean RM. Magnesium and its therapeutic uses: a review. Am J Med 1994; 96: 63-76.